Scan-based computer tool to predict kidney cancer recurrence before surgery
Tests a computer model using contrast CT scans in people with localized kidney cancer.
Key facts
- Who runs it
- Mingzhao Xiao
- Where
- Chongqing, ChinaSee the site
- Trial code
- Registry title
- Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- 1 Sept 2022
- Planned end
- 1 Aug 2025
- Type of study
- Observational, 2 groups
- Record updated
- 31 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with clear cell kidney cancer who had part or all of a kidney removed, and who have complete records and a CT scan from before surgery.
- Sex
- All sexes can join.
- Disease stage
- Clear cell renal cell carcinoma (ccRCC) confirmed under the microscope, in a single tumor with no spread (metastasis) at the time of surgery.
- Earlier treatment
- Had surgery to remove part of the kidney (partial nephrectomy) or the whole kidney (radical nephrectomy). Cannot have had treatment before or after surgery, such as neoadjuvant or adjuvant therapy.
- Biomarker or test result
- Must have a contrast-enhanced CT scan from before surgery that is good enough to analyze.
Main reasons for not taking part
- Incomplete clinical or pathology data
- No contrast-enhanced CT scan before surgery, or poor image quality
- Treatment before surgery (neoadjuvant) or after surgery (adjuvant)
- More than one tumor in the kidney
- Cancer that had already spread (metastasis) at the time of surgery
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- underwent partial/radical nephrectomies
- histologically diagnosed as ccRCC
- with complete clinical data and preoperative CT image data
Who cannot take part
- who received pre-surgery neoadjuvant or adjuvant therapies
- with incomplete clinic-pathological data
- lack of preoperative contrast-enhanced CT images or the image quality was unsuitable for analysis
- with multiple renal tumors or/and had synchronous metastasis
Where in China
- Yingjie XvChongqing, ChinaContact: Yingjie XvTaking people
About the trial
What the trial wants to find out
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's predictive ability with traditional models.
The 2 groups in the trial
- Non-recurrence group
- Recurrence group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Urology Department of the First Affiliated Hospital of Chongqing Medical University
- Plain-language title
- Scan-based computer tool to predict kidney cancer recurrence before surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 31 May 2025